Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 58 publications.

Curtis R, Decker-Palmer M, Wilson MR, McDade CL, Lin CW, Wallick C, Ko RH. Cost-effectiveness of emicizumab vs efanesoctocog alfa, standard half life (SHL) and other extended half life (EHL) FVIII products for prophylaxis in people with severe hemophilia a without inhibitors. Poster presented at the 65th ASH Annual Meeting & Exposition 2023; December 11, 2023. San Diego, CA. [abstract] Blood. 2023 Nov; 142(Supplement 1):5053-4. doi: 10.1182/blood-2023-181062

Dorling P, Luzzi R, McMichael A, Kent C, Canty E, Myers K, Badawy SM. Patients' preferences for dosing frequency and out-of-pocket cost associated with iron chelators: a mixed-methods pilot study in the United States. Poster presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition; December 7, 2023. San Diego, CA. [abstract] Blood. 2023 Nov; 142(Suppl 1):7203. doi: 10.1182/blood-2023-186416

Srivastava A, Rangarajan S, Ross C, Slota C, DiBenedetti D, Cano V, Andersson S, DasMahapatra P, Bartelt-Hofer J, Afonso M. Fitusiran reaches people's with hemophilia and their caregivers' treatment expectations: qualitative semi-structured interviews of participants of ATLAS-OLE Trial (Interim analysis). Poster presented at the American Society of Hematology (ASH) Annual Meeting 2022; December 11, 2022. New Orleans, LA. [abstract] Blood. 2022 Nov 15; 140(Suppl 1):7989-90. doi: 10.1182/blood-2022-166895

Joly F, DasMahapatra P, Su J, DiBenedetti D, Kosa K, Hill Q. Development of a cold Agglutinin disease-specific patient-reported outcome symptom measure. Poster presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 13, 2021. [abstract] Blood. 2021 Nov 23; 138(supplement 1):4057. doi: 10.1182/blood-2021-147199

Walters MC, Tisdale JF, Mapara MY, Krishnamurti L, Kwiatkowski JL, Aygun B, Kasow KA, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher ME, Zhang X, Ho PR, Thompson AA, Kanter J. Sustained improvements in patient-reported quality of life up to 24 months post-treatment with LentiGlobin for sickle cell disease (bb1111) gene therapy. Presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 11, 2021. Atlanta, Georgia. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):7. doi: 10.1182/blood-2021-146905

Germing U, Goyal RK, Yucel A, Parikh RC, Jimenez M, Sluga-O'Callaghan M, Tang D, Hughes C, Diez-Campelo M. Real-world evidence on treatment utilization in lower-risk myelodysplastic syndromes: findings from a medical record review in the United States. Poster presented at the 63rd ASH Annual Meeting and Exposition; December 11, 2021. Atlanta, GA. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):4666. doi: 10.1182/blood-2021-145576

Anderson S, Talbird S, Fishman J. Cost per responder analysis for pegcetacoplan and eculizumab in the treatment of adults with paroxysmal nocturnal hemoglobinuria. Blood. 2021;138(Suppl 1):4956. doi: 10.1182/blood-2021-153190

Sun SX, Olayinka-Amao O, DiBenedetti D. Assessing patient experiences with prophylactic treatments for hemophilia A: concept elicitation for gene therapy. Poster presented at the 62nd Annual Virtual Meeting of the American Society of Hematology (ASH); December 5, 2020. [abstract] Blood. 2020 Nov 5; 136(Suppl 1):33-4.

Spira AI, Chen L, Zhou X, Gnanasakthy A, Wang L, Ungar D, Curiel R, Radford JA, Kahl BS. Symptoms, health-related quality of life, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large b cell lymphoma. Blood. 2020 Nov 5;136(Suppl 1):3-4. doi: 10.1182/blood-2020-139571

Su J, Kosa K, DiBenedetti D. Patient-reported disease burden: in-depth interviews of patients with CAD. Poster presented at the 2020 Virtual 62nd ASH Annual Meeting and Exposition; December 6, 2020. [abstract] Blood. 2020 Nov 5; 136(Suppl 1):29-30.

Cohen AD, Hari P, Htut M, Berdeja JG, Madduri D, Usmani SZ, Allred AJ, Olyslager Y, Banerjee A, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau J, Deraedt W, Carrasco MJ, Akram M, Hossain F, Crawford R, Morrison R, Doward L, Jakubowiak A, Jagannath S. Patient expectations and perceptions of treatment in cartitude-1: phase 1b/2 study of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma. Poster presented at the 62nd Annual Virtual Meeting of the American Society of Hematology (ASH); December 2020. [abstract] Blood. 2020 Nov; 136(Suppl 1):13-6. doi: 10.1182/blood-2020-136383

Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang ML, Romaguera JE, Kaye JA. Overall survival, adverse events, and economic burden in Medicare-insured patients with mantle cell lymphoma receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):63. doi: 10.1182/blood-2019-122841

Allen LF, Aggarwal K, Vredenburg M, Barnett C, Mladsi D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 61st ASH American Society of Hematology Annual Meeting and Exposition; December 8, 2019. San Diego, CA. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):3454. doi: 10.1182/blood-2019-131822

Houghton K, Dimopoulos M, Lin PL, Guillonneau S, Bury S, Attal M, Richardson PG, Delforge M. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with isatuximab plus pomalidomide and dexamethasone: Icaria-MM study. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):1850. doi: 10.1182/blood-2019-128220

Goyal RK, Nagar SP, Kabadi SM, Davis KL, Le H, Kaye JA. Overall survival, adverse events, and economic burden in Medicare patients with chronic lymphocytic leukemia receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement 1):796. doi: 10.1182/blood-2019-122842

Dawson KL, Price MA, Torney PA, Gonzalez V, Sae-Hau M, Weiss E, Mange B, Mansfield C, Comenencia-Ortiz E, Masaquel A, Ravelo A. Patient-reported disease burden and age: results from a national patient advocacy survey of patients with chronic lymphocytic leukemia, diffuse large-B-cell lymphoma and follicular lymphoma. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):4778. doi: 10.1182/blood-2019-123644

Xie J, Yong A, Waweru C, Sorof TA, Goyal RK, Davis KL, Fellows G, Hillmen P. Real-world treatment patterns and adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib in the UK: a preliminary analysis. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):5885. doi: 10.1182/blood-2019-123025

Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez-Salas N, Martin-Richard M, Alonso-Orduna V, Vera R, Gallegeo J, Capdevila J, Salud A, Nogue M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X. Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial. JAMA Oncol. 2019 Aug 29;5(11):1566-73. doi: 10.1001/jamaoncol.2019.2294

Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, Copeland G, Meyer RE, Brown AL, Chambers TM, Sok P, Danysh HE, Carozza SE, Sisoudiya SD, Hilsenbeck SG, Janitz AE, Oster ME, Scheuerle AE, Schiffman JD, Luo C, Mian A, Mueller BA, Huff CD, Rasmussen SA, Scheurer ME, Plon SE. Association between birth defects and cancer risk among children and adolescents in a population-based assessment of 10 million live births. JAMA Oncol. 2019 Jun 20. doi: 10.1001/jamaoncol.2019.1215

Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Murthy S, Verma A, Shastri A. Risk stratification and transfusion dependence are independent risk factors for cardiovascular disease (CVD) in myelodysplastic syndrome (MDS). Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; November 13, 2019. [abstract] Blood. 2019; 134(Suppl 1):336. doi: 10.1182/blood-2019-123317

Auclair D, Mansfield C, Chari A, Cole CE, Fiala MA, Kaufman JL, Orloff G, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. Patient treatment preferences for relapsed/refractory multiple myeloma: are patients willing to trade off efficacy for tolerability? Presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; December 3, 2018. San Diego, CA. [abstract] Blood. 2018 Nov 29; 132(Supplement 1):614. doi: 10.1182/blood-2018-99-113087

Kabadi S, Goyal RK, Nagar SP, Kaye JA, Davis KL, Mato A. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Poster presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2, 2018. San Diego, CA. [abstract] Blood. 2018 Nov 29; 132(Supplement 1):3557. doi: 10.1182/blood-2018-99-114735

Emilsson L, Garcia-Albeniz X, Logan RW, Caniglia EC, Kalager M, Hernan MA. Examining bias in studies of statin treatment and survival in patients with cancer. JAMA Oncol. 2018 Jan 1;4(1):63-70. doi: 10.1001/jamaoncol.2017.2752

Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Murthy S, Verma A, Shastri A. Myelodysplastic Syndromes (MDS) are an independent risk factor for an earlier onset of myocardial infarction and increased mortality from Cardiovascular Disease (CVD). Poster presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; November 29, 2018. San Diego, CA. [abstract] Blood. 2018; 132(Suppl 1):3539. doi: 10.1182/blood-2018-99-115613

Karve S, Nagar S, Goyal R, Kaye JA, Mato AR. Adverse events, resource use, and economic burden in patients with mantle cell lymphoma in the United States. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3442. doi: 10.1182/blood.V130.Suppl_1.3442.3442

Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Castor Trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3400. doi: 10.1182/blood.V130.Suppl_1.3400.3400

Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Pollux trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 11, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):4711. doi: 10.1182/blood.V130.Suppl_1.4711.4711

Goyal R, Karve S, Nagar S, Kaye JA, Mato AR. Real-world treatment patterns and associated adverse events among patients with mantle cell lymphoma (MCL) in the United States. Blood. 2017 Dec;130(Suppl 1):5650. doi: 10.1182/blood.V130.Suppl_1.5650.5650

Mansfield C, Masaquel A, Sutphin J, Weiss ES, Gutierrez ME, Wilson J, Li J, Reyes C. What do patients prioritize in selecting chronic lymphocytic leukemia (CLL) treatments? Presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2016. San Diego, CA. [abstract] Blood. 2016 Dec 2; 128(22):1239. doi: 10.1182/blood.V128.22.1239.1239

Lin HM, Davis KL, Kaye JA, Luptakova K, Gao L, Nagar S, Seal B, Mohty M. Real-world clinical outcomes by cytogenetic risk category in relapsed or refractory multiple myeloma: evidence from a cohort review in France. Poster presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2016. San Diego, CA. [abstract] Blood. 2016 Dec 2; 128(22):4784. doi: 10.1182/blood.V128.22.4784.4784

Darden CM, Price MA, Kaye JA, Sherif BN, Marion S, Tzivelekis S, Garcia J, Chandler D. Same-day administration of pegfilgrastim following myelosuppressive chemotherapy: practices and rationale. Blood. 2015 Dec 3;126(23):5585. doi: 10.1182/blood.V126.23.5585.5585

Basch E, Geoghegan C, Coons SJ, Gnanasakthy A, Slagle AF, Papadopoulos EJ, Kluetz PG. Patient-reported outcomes in cancer drug development and US regulatory review perspectives from industry, the Food and Drug Administration, and the patient. JAMA Oncol. 2015 Apr 16. doi: 10.1001/jamaoncol.2015.0530

Davis KL, Cote I, Kaye JA, Gao H, Perez Ronco J, Seifeldin R, Mendelson E. Real-world assessment of clinical outcomes in lower-risk myelofibrosis patients receiving treatment with ruxolitinib. Poster presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition; December 6, 2014. San Francisco, CA. [abstract] Blood. 2014 Dec 6; 124(21):1857. doi: 10.1182/blood.V124.21.1857.1857

Casulo C, Byrtek M, Dawson K, Zhou X, Flowers C, Farber C, Hainsworth J, Cerhan J, Link B, Friedberg J. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National LymphoCare Study. Poster presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2014. San Francisco, CA. [abstract] Blood. 2014 Dec 6; 124(21):3044. doi: 10.1182/blood.V124.21.3044.3044

Goyal R, Davis KL, Cote I, Mounedji N, Kaye JA. Increased incidence of thromboembolic event rates in patients diagnosed with polycythemia vera: results from an observational cohort study. Poster presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition; December 6, 2014. San Francisco, CA. [abstract] Blood. 2014 Dec 6; 124(21):4840. doi: 10.1182/blood.V124.21.4840.4840

Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422

Clemens A, Abeysinghe S, Gonschior A-K, Hosel V, Lock S, Wolowacz SE, Woods M, Zimovetz E. Comparative efficacy and safety of dabigatran etexilate and rivaroxaban for the treatment of deep vein thrombosis and pulmonary embolism. Poster presented at the 55th ASH Annual Meeting; 2013. [abstract] Blood. 2013 Nov 15; 122(21):4807. doi: 10.1182/blood.V122.21.4807.4807

Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Link BK. PET compared with CT as a prognosticator after rituximab induction therapy in follicular lymphoma: report from the National LymphoCare Study. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):4245. doi: 10.1182/blood.V122.21.4245.4245

Nabhan C, Byrtek M, Dawson KL, Zhou X, Link BK, Friedberg JW. A proposed prognostic model for overall survival in the oldest old (>80 years old) follicular lymphoma patients. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):3058. doi: 10.1182/blood.V122.21.3058.3058

Casulo C, Byrtek M, Dawson K, Zhou X, Farber CM, Flowers CR. Early relapse of follicular lymphoma after R-CHOP uniquely defines patients at high risk for death: an analysis from the National LymphoCare Study. Presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2013. New Orleans, LA. [abstract] Blood. 2013 Nov; 122(21):510. doi: 10.1182/blood.V122.21.510.510

Davis KL, Price GL, Karve SJ, Pohl G, Walgren RA. Comorbidity burden in elderly persons with non-cml myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):1734. doi: 10.1182/blood.V120.21.1734.1734

Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA. Clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia: evidence from U.S. hospitals, 2007-2010. Presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):239. doi: 10.1182/blood.V120.21.239.239

Martin P, Link BK, Byrtek M, Dawson K, Ziemiecki RM, Friedberg J. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 8, 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):3702. doi: 10.1182/blood.V120.21.3702.3702

Karve SJ, Price GL, Davis KL, Pohl G, Walgren RA. Health care utilization and associated costs in elderly persons with myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):4273. doi: 10.1182/blood.V120.21.4273.4273

Price GL, Davis KL, Karve SJ, Pohl G, Walgren RA. Survival patterns in elderly patients with myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):428. doi: 10.1182/blood.V120.21.428.428

Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Treatment response patterns and related prognostic indicators in chronic myeloid leukemia patients: a multi-country medical record review study. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):3131. doi: 10.1182/blood.V118.21.3131.3131

Zhou X, Wang J, Zhang J, Copley-Merriman K, Torigoe Y, Reyes C. Symptoms and toxicity of rituximab maintenance (R-M) versus observation (OBS) following rituximab plus chemotherapy in patients with follicular lymphoma. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):3661. doi: 10.1182/blood.V118.21.3661.3661

Sinha R, Byrtek M, DeJoubner NJ, Nooka AK, Taylor M, Cerhan JR, Ziemiecki RM. Examining the outcomes of watchful waiting (WW) among US patients with advanced stage follicular lymphoma (FL). Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):775. doi: 10.1182/blood.V118.21.775.775

Henk HJ, Deeter R, Kaye JA, Becker LK, Legg JC, Rothman KJ. Effect of age on neutropenia-related hospitalization in Non-Hodgkin's lymphoma patients receiving myelosuppressive chemotherapy. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):2082. doi: 10.1182/blood.V118.21.2082.2082

Kiladjian J, Al-Ali H, Gisslinger H, Knoops L, Waltzman RJ, Mendelson E, Copley-Merriman K. Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):795. doi: 10.1182/blood.V118.21.795.795